Le Roy V, Delmas Y, Verdoux H
Université Victor-Segalen Bordeaux-2, Bordeaux, France.
Encephale. 2009 Dec;35(6):605-10. doi: 10.1016/j.encep.2008.12.007.
After 40 years of use of lithium in the treatment of mood disorders, the renal risks associated with the long-term exposure to lithium are better known.
This review is aimed at summarizing the information available in the literature regarding the impact of lithium on renal structure and function, the prevalence of renal abnormalities, the associated risk-factors and the strategy for their identification and management.
Articles were selected using a Medline search. The keywords were lithium, renal function, kidney, nephrotoxicity, renal insufficiency, side-effects, polyuria, diabetes insipidus and drug monitoring.
A well-recognized adverse effect of lithium exposure is the occurrence of nephrotic diabetes insipidus (NDI) resulting in polyuria and polydipsia, which occurs in 20% of the patients on long-term lithium treatment. This side-effect is linked to a deficit in urine concentrating ability. Its occurrence is associated with the duration of lithium therapy. Although this effect of lithium is initially functional and may disappear if the treatment is rapidly stopped, it may become structural and permanent over time. The decision to stop lithium or to treat the NDI with amiloride is mainly based upon its functional impact.
A debate has been ongoing for decades regarding whether or not the long-term use of lithium may cause slowly progressive renal failure. According to the recent literature, progressive renal failure occurs in approximately 20% of the patients on long-term lithium treatment, among whom a few develop severe renal insufficiency due to lithium (possibly in conjunction with other somatic factors) in the form of interstitial nephritis. However, there is an increasing number of reports of patients requiring dialysis after long-term exposure to lithium.
Current recommended strategies for minimising the renal side effects of lithium include: avoiding acute episodes of renal toxicity; monitoring serum lithium concentrations in order to achieve optimal efficacy at the lowest possible concentrations; monitoring serum creatinine levels at least on a yearly basis, with discontinuation of lithium use, discussion with a nephrologist if creatinine clearance decreases below 60 ml/mn; and the possible application of lithium into single daily dose.
锂用于治疗心境障碍已有40年,长期接触锂相关的肾脏风险已广为人知。
本综述旨在总结文献中有关锂对肾脏结构和功能的影响、肾脏异常的患病率、相关危险因素以及其识别和管理策略的可用信息。
通过Medline检索选择文章。关键词为锂、肾功能、肾脏、肾毒性、肾功能不全、副作用、多尿、尿崩症和药物监测。
锂暴露一个公认的不良反应是发生肾性尿崩症(NDI),导致多尿和烦渴,长期接受锂治疗的患者中有20%会出现这种情况。这种副作用与尿液浓缩能力缺陷有关。其发生与锂治疗的持续时间相关。虽然锂的这种作用最初是功能性的,如果迅速停药可能消失,但随着时间推移可能会变成结构性和永久性的。停用锂或用氨氯吡咪治疗NDI的决定主要基于其功能影响。
关于长期使用锂是否会导致缓慢进展性肾衰竭的争论已经持续了几十年。根据最近的文献,长期接受锂治疗的患者中约20%会发生进行性肾衰竭,其中少数患者会因锂(可能与其他躯体因素共同作用)以间质性肾炎的形式发展为严重肾功能不全。然而,越来越多关于长期接触锂后需要透析的患者报告。
目前推荐的将锂的肾脏副作用降至最低的策略包括:避免急性肾毒性发作;监测血清锂浓度以在尽可能低的浓度下达到最佳疗效;至少每年监测血清肌酐水平,若肌酐清除率降至60 ml/分钟以下则停用锂,并与肾病学家讨论;以及可能将锂应用于每日单次剂量。